Healthcare (SH:603313) HTSC·2025-10-30 06:40Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of RMB 12.20 [6][4]. Core Views - The company reported a revenue of RMB 6.756 billion for the first three quarters of 2025, representing a year-on-year increase of 10.29%, and a net profit attributable to the parent company of RMB 161 million, up 205.18% year-on-year [1][6]. - The growth in revenue is attributed to the recovery of domestic and international sales, improvements in the business structure, and a reduction in credit impairment losses compared to the same period last year [1][4]. - The company is expected to continue benefiting from its global production capacity layout, particularly in North America, and is actively expanding its brand and channel development in the domestic market [1][4]. Summary by Sections Revenue and Profitability - For Q3 2025, the company achieved a revenue of RMB 2.440 billion, a year-on-year increase of 11.98%, with a net profit of RMB 46.35 million, up 122.55% year-on-year [1][6]. - The gross profit margin for the first three quarters of 2025 increased by 2.3 percentage points to 39.5%, driven by product upgrades and business structure optimization [3][4]. Sales Performance - The company's overseas revenue for the first three quarters of 2025 increased by 9.34% to RMB 5.374 billion, with North America leading the growth at 10.49% to RMB 3.466 billion [2][4]. - Domestic sales also showed strong performance, with a year-on-year increase of 11.59% to RMB 1.171 billion [2][4]. Cost Structure - The selling expense ratio increased by 2.8 percentage points to 25.6%, reflecting the company's investment in brand building [3][4]. - The financial expense ratio decreased by 1.9 percentage points to 2.4%, benefiting from adjustments in financing structure and reduced interest expenses [3][4]. Future Outlook - The company is expected to maintain steady revenue growth due to its global production network and unique positioning in the domestic market, particularly in the memory foam category [1][4]. - Profit forecasts for 2025-2027 have been adjusted, with net profits projected at RMB 239 million, RMB 348 million, and RMB 461 million respectively [4][10].